<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T1" position="float">
 <label>Table 1</label>
 <caption>
  <title>Selected clinical trials on prevention and treatment of COVID-19 with licensed drugs or substances under clinical development*
   <sup>1</sup>
  </title>
 </caption>
 <table frame="hsides" rules="all">
  <thead>
   <tr>
    <td valign="top" rowspan="1" colspan="1">
     <bold>Substance</bold>
    </td>
    <td valign="top" rowspan="1" colspan="1">
     <bold>Brief description of trial</bold>
    </td>
    <td valign="top" rowspan="1" colspan="1">
     <bold>Number of participants</bold>
    </td>
    <td valign="top" rowspan="1" colspan="1">
     <bold>Institution/sponsor</bold>
    </td>
    <td valign="top" rowspan="1" colspan="1">
     <bold>Country</bold>
    </td>
    <td valign="top" rowspan="1" colspan="1">
     <bold>Planned completion</bold>
    </td>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top" rowspan="1" colspan="1">Chloroquine</td>
    <td valign="top" rowspan="1" colspan="1">Prevention, placebo-controlled trial (1:1 randomization)
     <break/>Participants: Employees in a health care facility or other persons at high risk of infection, e.g., relatives of patients with COVID-19
     <break/>Treatment: Placebo or 10 mg chloroquine base/kg, thereafter 250 mg chloroquine phosphate daily for 3 months 
    </td>
    <td valign="top" rowspan="1" colspan="1">10 000</td>
    <td valign="top" rowspan="1" colspan="1">University of Oxford</td>
    <td valign="top" rowspan="1" colspan="1">UK</td>
    <td valign="top" rowspan="1" colspan="1">May 2022 </td>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1">Chloroquineplus darunavir/cobicistat </td>
    <td valign="top" rowspan="1" colspan="1">Open trial
     <break/>Participants: Patients with positive COVID-19 test result
     <break/>Treatment: 800 mg darunavir (plus 150 mg cobicistat as booster) for 7 days together with chloroquine; contacts receive 1 g chloroquine phosphate on days 1 and 2, 0.5 g on day 3 
    </td>
    <td valign="top" rowspan="1" colspan="1">2900</td>
    <td valign="top" rowspan="1" colspan="1">Lihir Medical Center</td>
    <td valign="top" rowspan="1" colspan="1">Spain (Catalonia)
     <break/>Department of Health, Generalitat de Catalunya 
    </td>
    <td valign="top" rowspan="1" colspan="1">July 2020</td>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1">Hydroxychloroquine</td>
    <td valign="top" rowspan="1" colspan="1">Open trial, pilot study
     <break/>Participants: Patients with pneumonia from SARS-CoV-2
     <break/>Treatment: 400 mg hydroxychloroquine daily for 5 days 
    </td>
    <td valign="top" rowspan="1" colspan="1">30</td>
    <td valign="top" rowspan="1" colspan="1">Shanghai Public Health Clinical Center</td>
    <td valign="top" rowspan="1" colspan="1">China</td>
    <td valign="top" rowspan="1" colspan="1">August 2020</td>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1">Remdesivir</td>
    <td valign="top" rowspan="1" colspan="1">Placebo-controlled double-blind trial (1:1 randomization)
     <break/>Participants: Moderately to severely ill patients with PCR-confirmed COVID-19, max. 12 days since disease onset; oxygen saturation SaO 2 /SpO 2 ≤ 94% at time of admission
     <break/>Treatment: 200 mg remdesivir i.v. on day 1, then 100 mg daily for a total of 9 days
     <break/>Comment: A similarly designed trial is being carried out simultaneously in 308 patients with mild symptoms. 
    </td>
    <td valign="top" rowspan="1" colspan="1">453</td>
    <td valign="top" rowspan="1" colspan="1">Capital Medical University
     <break/>Peking 
    </td>
    <td valign="top" rowspan="1" colspan="1">China</td>
    <td valign="top" rowspan="1" colspan="1">April 2020</td>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1">Remdesivir </td>
    <td valign="top" rowspan="1" colspan="1">Open trial, comparison with standard treatment
     <break/>Participants: Severely ill patients with PCR-confirmed COVID-19 (max. 4 days since diagnosis); oxygen saturation SaO 2 /SpO 2 ≤ 94% at time of admission; radiological demonstration of pulmonary infiltrates
     <break/>Treatment: 200 mg remdesivir i.v. on day 1, then 100 mg daily for a total of 5 or 10 days
     <break/>Comment: A similarly designed trial is being carried out simultaneously in 600 patients with moderate symptoms (SpO 2 &gt;94%) 
    </td>
    <td valign="top" rowspan="1" colspan="1">400</td>
    <td valign="top" rowspan="1" colspan="1">Gilead Sciences</td>
    <td valign="top" rowspan="1" colspan="1">USA</td>
    <td valign="top" rowspan="1" colspan="1">May 2020</td>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1">Lopinavir/ritonavir Arbidol Oseltamivir </td>
    <td valign="top" rowspan="1" colspan="1">Open randomized trial
     <break/>Participants: Patients with PCR-confirmed COVID-19 and demonstration of pneumonia on CT
     <break/>Treatment (four groups):
     <break/>a) Symptomatic standard treatment
     <break/>b) Plus umifenovir* 
     <sup>2</sup> 3 × 200 mg/day for 2 weeks
     <break/>c) Plus oseltamivir 2 × 75 mg/day for 2 weeks
     <break/>d) Plus lopinavir/ritonavir 2 × 500 mg/day for 2 weeks 
    </td>
    <td valign="top" rowspan="1" colspan="1">400</td>
    <td valign="top" rowspan="1" colspan="1">Tongji Hospital</td>
    <td valign="top" rowspan="1" colspan="1">China</td>
    <td valign="top" rowspan="1" colspan="1">July 2020</td>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1">Thalidomide</td>
    <td valign="top" rowspan="1" colspan="1">Placebo-controlled double-blind trial
     <break/>Participants: Patients with PCR-confirmed COVID-19 (max. 8 days since diagnosis); pulmonary findings on imaging
     <break/>Treatment: 1 × 100 mg thalidomide or placebo daily for 14 days 
    </td>
    <td valign="top" rowspan="1" colspan="1">100</td>
    <td valign="top" rowspan="1" colspan="1">Second Affiliated Hospital of Wenzhou Medical University</td>
    <td valign="top" rowspan="1" colspan="1">China</td>
    <td valign="top" rowspan="1" colspan="1">June 2020</td>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1">rh-ACE2 </td>
    <td valign="top" rowspan="1" colspan="1">Pilot study, open design
     <break/>Participants: Patients with PCR-confirmed diagnosis, oxygen saturation ≤ 93%
     <break/>Treatment: 12 patients with 2 × 0.4 mg/kg recombinant human ACE2 i.v. daily, max. 7 days
     <break/>12 patients with standard treatment 
    </td>
    <td valign="top" rowspan="1" colspan="1">24</td>
    <td valign="top" rowspan="1" colspan="1">First Affiliated Hospital of Guangzhou Medical University</td>
    <td valign="top" rowspan="1" colspan="1">China</td>
    <td valign="top" rowspan="1" colspan="1">April 2020</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>*
   <sup>1</sup> Altogether, &gt;80 trials have been registered at 
   <ext-link ext-link-type="uri" xlink:href="www.clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">www.clinicaltrials.gov</ext-link>; *
   <sup>2</sup> designation in some studies registered at 
   <ext-link ext-link-type="uri" xlink:href="www.clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">www.clinicaltrials.gov</ext-link>: abidol/arbidol
  </p>
  <p>ACE2, Angiotensin-converting enzyme 2; CT, computed tomography; i.v., intravenous; PCR, polymerase chain reaction; rh, recombinant human</p>
 </table-wrap-foot>
</table-wrap>
